# Aspivix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aspivix

- Industry: Medical Devices & Equipment
- Headquarters: Switzerland
- Website: www.aspivix.com
- Total disclosed funding: $6.8M
- Latest round: Series A (Nov 17, 2022)
- Investors on record: 5

## About

Based in Switzerland, Aspivix SA specializes in developing and commercializing innovative healthcare solutions, particularly the Carevix® device, which offers a less painful approach to gynecological procedures.Aspivix SA is focused on creating advanced medical devices, specifically the Carevix® device, which provides a soft-suction alternative to traditional gynecological tools. Founded in 2015 by Julien Finci and Mathieu Horras, the company has completed two funding deals, with the most recent being a Series A round in November 2022, raising USD 5.000 mn led by Hemex AG and supported by other investors such as 4FOx Venture, Launchpad APAC, and Zürcher Kantonalbank.Aspivix is engaged in the development and commercialization of the Carevix® device, which serves as a modern soft-suction cervical stabilizer, providing a less painful alternative to the tenaculum for gynecological procedures, particularly during IUD insertion. The device aims to reduce discomfort and bleeding associated with these procedures, addressing a significant need as many women experience pain during IUD placements. Cleared for use by the FDA in the United States and CE-marked for Europe, the Carevix® is also authorized in the UK and Brazil, targeting both healthcare professionals and women seeking effective contraceptive solutions.Aspivix generates revenue through the sale of its flagship product, Carevix®, sold directly to healthcare providers and clinics specializing in gynecological services. The sales model enables healthcare providers to enhance patient experiences during IUD placements, with pricing reflecting its innovative design and the clinical benefits it offers.Aspivix plans to utilize the USD 5.000 mn raised in Series A funding to enhance product research and development, with a focus on expanding its market presence in the United States and the UK. The company aims to introduce new products aimed at improving gynecological care and to solidify its position in these key markets.

## Funding rounds

- Series A, Nov 17, 2022, $5M — Zürcher Kantonalbank, 4FOx Venture, Launchpad APAC, Hemex AG
- Series A, Aug 20, 2018, $1.8M — Zürcher Kantonalbank, Business Angels Suisse, 4FOx Venture

## Investors

- Zürcher Kantonalbank — Series A
- Business Angels Suisse — Series A
- 4FOx Venture — Series A
- Launchpad APAC — Series A
- Hemex AG (https://capitalatlas.ai/funds/hemex-ag) — Series A